Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPh201 in Ischemic Optic Neuropathy
NCT02045212Phase 2Completed
- Sponsor
- Regenera Pharma
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) and traumatic optic neuropathy (TON) comparing RPh201 with Placebo (2 arms). Primary endpoints: Mean Increase From Baseline in ETDRS Letters Read at 39 weeks, Changes in Visual Field at 26 weeks and 1 more. Started Feb 2014; status: completed.
02
Drugs
RPh201
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)traumatic optic neuropathy (TON)
Beyond the preview
Go deeper on NCT02045212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045212.